Elevation Oncology's market valuation is poised to drop 50% due to updates on their Claudin ADC, EO-3021. EO-3021, their main project, showed promising response rates in early-stage studies, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback